Tuberculosis: Are we making it incurable?

European Respiratory Journal

Volumn 42, Issue 1, 2013, Pages 5-8

  Caminero, José A ^a,b   Matteelli, Alberto ^c   Loddenkemper, Robert ^d  

^a HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^b INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^c UNIVERSITY OF BRESCIA   (Italy)

^d German Central Committee Against Tuberculosis DZK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; CAPREOMYCIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; QUINOLONE DERIVATIVE; RIFAMPICIN; STREPTOMYCIN; TERIZIDONE; THIOACETAZONE;

ANTIBIOTIC RESISTANCE; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; HUMAN; INFECTION CONTROL; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT DURATION; TREATMENT PLANNING; TUBERCULOSIS;

ANTI-BACTERIAL AGENTS; ANTITUBERCULAR AGENTS; DRUG RESISTANCE, BACTERIAL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84880162788     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00206712     Document Type: Review

References (29)

1. Caminero JA, Torres A. Controversial topics in tuberculosis. Eur Respir J 2004; 24: 895. (Pubitemid 39642274)
2. Stead WW. Variation in vulnerability to tuberculosis in America today: random, or legacies of different ancestral epidemics? Int J Tuberc Lung Dis 2001; 5: 807-814. (Pubitemid 32843673)
3. Grzybowski S, Enarson DA. The fate of cases of pulmonary tuberculosis under various treatment programmes. Bull Int Union Tuberc Lung Dis 1978; 53: 70-75. (Pubitemid 9240283)
4. Caminero JA. A tuberculosis guide for specialist physicians. Paris, International Union Against Tuberculosis and Lung Disease, 2003.
5. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999; 3: Suppl. 2, S231-S279. (Pubitemid 29481843)
6. Streptomycin treatment of pulmonary tuberculosis. BMJ 1948; 2: 769-783.
7. Caminero JA, Sotgiu G, Zumla A, et al. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 2010; 10: 621-629.
8. Orenstein EW, Basu S, Shah NS, et al. Treatment outcome among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 153-161.
9. Johnston JC, Shahidi NC, Sadatsafavi M, et al. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One 2009; 4: e6914.
10. Jacobson KR, Tierney DB, Jeon CY, et al. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 2010; 51: 6-14.
11. Chan ED, Laurel V, Strand MJ, et al. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2004; 169: 1103-1109. (Pubitemid 38624789)
12. Chiang CY, Enarson DA, Yu MC, et al. Outcome of pulmonary multidrug-resistant tuberculosis: a 6-year follow-up study. Eur Respir J 2006; 28: 980-985. (Pubitemid 46331968)
13. Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 2013; 42: 156-168.
14. Migliori GB, Sotgiu G, Gandhi NR, et al. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J 2013; 42: 169-179.
15. World Health Organization, Stop TB Partnership. The global MDR-TB & XDR-TB response plan 2007-2008. Geneva, World Health Organization, 2007.
16. Migliori GB, Besozzi G, Girardi E, et al. Clinical and operational value of the extensively drug-resistant tuberculosis definition. Eur Respir J 2007; 30: 623-626. (Pubitemid 351194820)
17. Caminero JA. Extensively drug-resistant tuberculosis: is its definition correct? Eur Respir J 2008; 32: 1413-1415.
18. Ahuja SD, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PloS Med 2012; 9: e1001300.
19. Falzon D, Jaramillo E, Schünemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38: 516-528.
20. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008. Geneva, World Health Organization, 2008.
21. Caminero JA. Treatment of multidrug-resistant tuberculosis: evidence and controversies. Int J Tuberc Lung Dis 2006; 10: 829-837. (Pubitemid 44197841)
22. Zierski M, Zachara A. Late results in re-treatment of patients with pulmonary tuberculosis. Tubercle 1970; 51: 172-177.
23. Tousek J, Jancik E, Zelenka M, et al. The results of treatment in patients with cultures resistant to streptomycin, isoniazid and PAS: a five-year follow-up. Tubercle 1967; 48: 27-31.
24. Pines A. The fate of patients with drug-resistant tubercle bacilli and pulmonary tuberculosis. Br J Dis Chest 1962; 56: 163-170.
25. Mitnick CD, Shin SS, Seung KJ, et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med 2008; 359: 563-574.
26. Migliori GB, Sotgiu G, D'Ambrosio L, et al. TB and MDR/XDR-TB in European Union and European Economic Area countries: managed or mismanaged? Eur Respir J 2012; 39: 619-625.
27. Sotgiu G, D'Ambrosio L, Centis R, et al. TB and M/XDR-TB infection control in European reference centres: the Achilles' heel? Eur Respir J 2011; 38: 1221-1223.
28. Loddenkemper R, Sotgiu G, Mitnick CD. Cost of tuberculosis in the era of multidrug resistance: will it become unaffordable? Eur Respir J 2012; 40: 9-11.
29. Grosset JH, Singer TG, Bishai WR. New drugs for the treatment of tuberculosis: hope and reality. Int J Tuberc Lung Dis 2012; 16: 1005-1014.